aluminum nickel

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 各种混合金属/非金属
• 英文名称: aluminum nickel
• 英文别名: nickel monoaluminide；nickel aluminide；nickel-aluminum；raney nickel；alumane;nickel
• 化学式: AlNi
• 分子量: 85.6715
• InChiKey: YYCNOHYMCOXPPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.19
• 重原子数：
  2
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  aluminum nickel 在 air 作用下， 以 neat (no solvent) 为溶剂， 生成 alumina
  参考文献：
  名称：

  在 1100 °C 氧化过程中，伴随着 (111) NiAl 上形成保护层的 α-氧化铝的横向生长动力学

  摘要：

  在 (111) NiAl 在 1100 °C 氧化的早期阶段，氧化铝鳞片形成并经历一系列同素异形相变。在相发展的最后阶段，亚稳态 Θ-氧化铝转变为平衡 α-氧化铝相。使用来自鳞片中痕量 Cr3+ 杂质的光致发光形成的图像，结合扫描电子显微镜，表明 α-氧化铝通过 θ-氧化铝基质内的成核和生长过程形成。不断增长的 α-氧化铝岛的横向冲击与报道的氧化动力学下降到 NiAl 长期氧化的特征相吻合。与大多数界面控制的转变不同，横向生长中 θ-to-α 转变的动力学被发现是对数的。提出了这些异常动力学的可能原因。

  DOI：

  10.1063/1.118917
• 作为产物：
  描述：

  以 neat (no solvent, solid phase) 为溶剂， 生成 aluminum nickel
  参考文献：
  名称：

  Magnetic properties of a non-equilibrium Al(Fe–Ni) alloy powder by rod-milling and chemical leaching

  摘要：

  In this paper, the magnetic properties of non-equilibrium nanocrystalline phase by chemical leaching of as-milled Al-0.6(Fe0.5Ni0.5)(0.4) powder is reported. X-ray diffractometry (XRD), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), vibrating sample magnetometry (VSM), and superconducting quantum interference device magnetometry ( SQUID) were used to characterize the as-milled powder and leached specimens. The saturation magnetization M-s decreased approximately 15 times than that of the powder before milling. Magnetization sharply increased to approximately 580 degrees C, when cooling of the specimen from 750 degrees C. The broad peaks of the magnetization shifted towards a lower-temperature side and the peak intensity increased, with increasing external field. The irreversibility between the field-cooling (FC) and zero-field cooling (ZFC) for the specimen begins greatly above the wide ZFC magnetization maximum and occurs at relatively high temperature. The magnetization is higher at lower temperatures, with increasing external field. (c) 2008 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jmmm.2008.02.109
• 作为试剂：
  描述：

  N-甲基-4-吡啶甲酰胺 在 氢氧化钾 、 aluminum nickel 作用下， 以 甲醇 为溶剂， 反应 2.5h， 生成 N-甲基哌啶-4-羧酰胺
  参考文献：
  名称：

  Facile reduction of pyridines with nickel-aluminum alloy

  摘要：

  DOI：

  10.1021/jo00354a021

文献信息

• Compositions and method comprising heterocyclic compounds containing two
  申请人：——

  公开号：US05030629A1

  公开（公告）日：1991-07-09

  A method and compositions for enhancing absorption of topically administered physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for local or systemic use, comprising a therapeutically effective amount of a pharmaceutically active agent and a non-toxic, effective amount of penetration enhancing agent of the formula I: ##STR1## wherein R is a saturated or unsaturated, straight or branched, cyclic or acyclic hydrocarbon group with from 1 to 19 carbon atoms, alkoxyalkyl, haloalkyl, specifically trifluoromethyl, alkoxy, amino, alkylamino and acylamino; R' and R" are hydrogen, alkyl, trifluoromethyl, alkoxyalkyl, aminoalkyl, alkyl- and acylaminoalkyl, carboxy, carbalkoxy, hydroxyalkyl or lower alkyl ester thereof; X is O or NR.sub.1 wherein R.sub.1 is hydrogen, alkyl, alkenyl, alkoxyalkyl, carbalkoxyalkyl, aminoalkyl, alkyl- and acylaminoalkyl, hydroxyalkyl or hydroxyalkyloxyalkyl and lower alkyl ester thereof; and n is 2 or 3 are disclosed.

  一种用于增强人类和动物皮肤和黏膜对经皮设备或制剂中局部或全身使用的局部应用生理活性药物的吸收的方法和组合物，包括治疗有效量的药用活性剂和公式I的非毒性、有效量的渗透增强剂：##STR1## 其中R是具有1至19个碳原子的饱和或不饱和、直链或支链、环状或非环状的烃基，烷氧基烷基，卤代烷基，特别是三氟甲基，烷氧基，氨基，烷基氨基和酰氨基；R'和R"是氢，烷基，三氟甲基，烷氧基烷基，氨基烷基，烷基和酰氨基烷基，羧基，羧酸烷氧基，羟基烷基或其较低烷基酯；X是O或NR.sub.1，其中R.sub.1是氢，烷基，烯烃基，烷氧基烷基，羧酸烷氧基烷基，氨基烷基，烷基和酰氨基烷基，羟基烷基或羟基烷氧基烷基及其较低烷基酯；n为2或3。
• Fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05852045A1

  公开（公告）日：1998-12-22

  Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##

  纤维蛋白原受体拮抗剂具有如下结构，例如，##STR1## 例如 ##STR2##
• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Salts of dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and
  申请人：Eli Lilly and Company

  公开号：US04252954A1

  公开（公告）日：1981-02-24

  Salts of 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and hindered amines, useful in combating influenza A and B.

  6,7-二卤-3,4-二氢-3-氧代-2-喹喔啉羧酸盐和阻隔胺类化合物，可用于对抗甲型和乙型流感。
• (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and
  申请人：Ciba-Geigy Corporation

  公开号：US05025025A1

  公开（公告）日：1991-06-18

  Disclosed are the compounds of formula ##STR1## wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower alkenylene, phenylene or a direct bond; M represents lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl, sulfonyl- or thio)-lower alkylene, lower alkenylene or a direct bond; or one of A, B and M represents lower alkylidenylene and the other two independently represent lower alkylene; R represents hydrogen unless A, B or M represents lower alkylidenylene in which case R represents the second bond to the adjacent aklylidenylene unsaturated carbon atom; Het represents 1-imidazolyl, 3-pyridyl, or 1-imidazolyl or 3-pyridyl substituted by lower alkyl; Ar represents carbocyclic or heterocyclic aryl; pharmaceutically acceptable ester and amide derivatives thereof; the N-oxides of said compounds wherein Het represents optionally substituted pyridyl; the said compounds of formula I wherein COOH is replaced by 5-tetrazolyl; and the pharmaceutically acceptable salts; which are useful as thromboxane synthetase inhibitors and thromboxane receptor antagonists.

  揭示了以下式的化合物##STR1##其中A代表较低的烷基; B代表氧、硫、较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基、苯基或直接键; M代表较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基或直接键; 或者A、B和M中的一个代表较低的烷基亚烯基，另外两个独立地代表较低的烷基; R代表氢，除非A、B或M代表较低的烷基亚烯基，在这种情况下R代表相邻烷基亚烯基不饱和碳原子的第二键; Het代表1-咪唑基、3-吡啶基，或者被较低烷基取代的1-咪唑基或3-吡啶基; Ar代表碳环或杂环芳基; 其药学上可接受的酯和酰胺衍生物; 其中Het代表可选择取代的吡啶基的N-氧化物; 公式I中COOH被5-四唑基取代的所述化合物; 和药学上可接受的盐; 这些化合物可用作血栓素合酶抑制剂和血栓素受体拮抗剂。